Novartis Profit, Sales Decline as Generic Competition Bites
Novartis AG’s profit fell more than estimated and sales unexpectedly declined in the first quarter as some of…
Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies
A weak Q1 for Novartis that was heavily impacted by generics erosion showcases that the billions of dollars…
Novartis to Spend $70 Million More on R&D Each Month for Avidity
Novartis AG will spend as much as $70 million each month on research and development to advance Avidity…
New CFO with Novartis experience
Mukul Mehta succeeds Harry Kirsch as Novartis CFO in March. Kirsch had been CFO since 2013 and is…